0.86
+5.44%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About TELA Bio
From its filings with the US Securities and Exchange Commission
TELA Bio is based in Malvern, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TELA. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $80.3m and a net loss of $38.8m. At that date it held total assets of $81.4m and shareholders' equity of $6.3m.
We are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Our growing product portfolio is purposefully designed to leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. We are committed to delivering our advanced technologies with a strong economic value proposition to assist surgeons and institutions in providing next-generation soft-tissue repair solutions to more patients worldwide.
We are dedicated to building true partnerships with surgeons and healthcare providers to deliver solutions that provide both clinical and economic improvements. We believe that genuine collaboration with surgeons and healthcare providers results in the development of new solutions that empower patient care and addresses unmet needs within the soft tissue reconstruction market.
Our first portfolio of products, the OviTex Reinforced Tissue Matrix (“OviTex”) which we first commercialized in the U.S. in July 2016 and in Europe in February 2019, addresses unmet needs in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials while minimizing their shortcomings, at a cost-effective price.
Quoted from its 10-K, filed 25 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 8 Nov 2019
- Employees
- 218
- Website
- telabio.com ↗
- Head office
- 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA, 19355
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Douglas EvansIndependent Chairman of the Board$148,697
- Mr. Jeffrey BlizardPresident, since 2024$88,395
- Mr. Antony KoblishChief Executive Officer, Co-Founder, Director, since 2012$2.1m
- Mr. Roberto CucaChief Financial Officer, Chief Operating Officer$1.1m
- Mr. Paul TalmoChief Technology Officer$816,614
- Mr. Greg FirestoneChief Commercial Officer
- Mr. Kurt AzarbarzinIndependent Director$105,252
- Mr. Vince BurgessIndependent Director$107,683
- Ms. Federica O'BrienIndependent Director$112,683
- Mr. William PlovanicIndependent Director
- Dr. Betty Jo RocchioIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 43
- Environment
- 28
- Social
- 53
- Governance
- 47
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- TELA Bio Inc is positioned as a leading medical technology company specializing in advanced surgical solutions. The company's core strengths include:
- TELA Bio offers a range of innovative surgical products tailored to meet the needs of healthcare professionals. These products have been developed based on extensive research and clinical data, ensuring their efficacy and safety.
- TELA Bio has successfully established its presence in the market and has a strong track record of delivering high-quality solutions to healthcare providers. This track record helps build credibility and trust among potential customers.
Weaknesses
- TELA Bio Inc has identified the following weaknesses that warrant attention:
- Despite its achievements, TELA Bio has a relatively limited market reach, primarily due to intense competition and challenges in penetrating new markets. Expanding its reach and market share may require significant investments and strategic partnerships.
- As a medical technology company, TELA Bio is highly dependent on regulatory approvals to bring its products to market. Delays or rejections in obtaining regulatory clearance may hinder the company's growth and expansion plans.
Opportunities
- TELA Bio Inc can leverage the following opportunities to drive its future success:
- There is an increasing demand for innovative surgical solutions that provide improved patient outcomes and reduced healthcare costs. TELA Bio can capitalize on this trend by continuously developing and introducing advanced products that address unmet medical needs.
- TELA Bio can explore opportunities to expand its market presence in untapped geographical regions. By strategically identifying target markets and establishing strong distribution networks, the company can increase its reach and revenue potential.
Threats
- TELA Bio Inc must be cautious of the following threats that may impact its business:
- The medical technology industry is highly competitive, with numerous players vying for market share. TELA Bio faces the threat of competitors introducing similar or superior products, potentially reducing its market position.
- Regulatory frameworks governing the medical technology sector may undergo changes, posing challenges for TELA Bio's product development and commercialization efforts. It is crucial for the company to stay updated with evolving regulations and adapt accordingly.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.